Article Figures & Data
Tables
- Table 1
- Saudi Initiative of Bronchiolitis Diagnosis, Management, and Prevention recommendations on using Palivizumab across different patients’ categories.11
Patient segment Recommendations Level of evidence Early preterm (=28 weeks, 6 days GA) ≤12 months of age 1B Mid preterm (29 weeks GA, 0 days to 32 weeks, 6 days GA) ≤6 months of age 1B Late preterm (33 weeks, 0 days weeks GA to 35 weeks, 0 days GA) ≤6 months of age at the start of the RSV season OR born during RSV season with at least one of the following risk factors: Attendance at child care Children <5 years of age who live permanently in the same household (including siblings) Exposure to environmental air pollutants 1B Infants and children with CLD <12 months for all; <24 months if still receiving medications for CLD within 6 months from the beginning of the epidemic season 1B Infants and children with hemodynamically significant CHD <12 months for all; <24 months if still receiving medications for the cardiac condition <6 months from the beginning of the epidemic season. Postoperative dose after cardio bypass 1B Children with anatomic pulmonary abnormalities or neuromuscular disorders <24 months may be considered for infants with impaired ability to handle respiratory secretions. 3B Immunocompromised children <24 months may be considered for children who are profoundly immunocompromised during the RSV season 2B Children with down syndrome Recommended for children with accompanying qualifying heart disease, CLD, airway clearance issues, or premature birth (<35 weeks, 0 days GA) 2B Children with cystic fibrosis <12 months with clinical evidence of CLD and/or nutritional compromise for <24 months with manifestations of severe lung disease or weight for length <10th percentile 2A Special situations: If an infant who is receiving prophylaxis experiences a breakthrough of RSV If an infant who is receiving prophylaxis experiences a breakthrough of RSV, the monthly prophylaxis should continue as planned until a maximum of 5 doses have been administered 3B RSV: Respiratory Syncytial Virus, CLD: chronic lung disease, CHD: congenital heart disease, GA: gestational age
In this issue
Jump to section
- Article
- Abstract
- 1. Introduction
- 2. Respiratory syncytial virus epidemiology, immunoprophylaxis, and management in KSA
- 3. Status of RSV immunoprophylaxis program
- 4. Saudi Initiative of Bronchiolitis Diagnosis, Management, and Prevention (SIBRO)
- 5. Respiratory syncytial virus immunoprophylaxis programs in the era of COVID-19 in the KSA
- 6. Future of RSV amid COVID-19
- 7. Conclusion
- Acknowledgment
- Footnotes
- References
- Figures & Data
- eLetters
- References
- Info & Metrics
Related Articles
Cited By...
- No citing articles found.